Evidence map›Paper›PMID 42262689›Full record

ArticleInternational journal of clinical oncology2026

Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs.

Tetsu Hirakawa, Kakuhiro Yamaguchi, Kiyofumi Shimoji, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Hiroshi Iwamoto, Hironobu Hamada, Noboru Hattori

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Tetsu HirakawaDepartment of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.ORCID http://orcid.org/0009-0007-9091-3397
Kakuhiro YamaguchiDepartment of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan. yamaguchikakuhiro@gmail.com.ORCID http://orcid.org/0000-0002-9117-1934
Kiyofumi ShimojiDepartment of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.ORCID http://orcid.org/0000-0001-5382-4730
Shinjiro SakamotoDepartment of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Yasushi HorimasuDepartment of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.ORCID http://orcid.org/0000-0002-3390-8491
Takeshi MasudaDepartment of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.ORCID http://orcid.org/0000-0003-3557-0049
Taku NakashimaDepartment of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.ORCID http://orcid.org/0000-0002-0035-674X
Hiroshi IwamotoDepartment of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.ORCID http://orcid.org/0000-0003-4922-5334
Hironobu HamadaDepartment of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID http://orcid.org/0000-0002-7979-0708
Noboru HattoriDepartment of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVascular endothelial growth factor (VEGF)-A, which is overexpressed in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), has been implicated in resistance to EGFR-tyrosine kinase inhibitors (TKIs). VEGF-A comprises several isoforms, including VEGF

methodsWe retrospectively analyzed 64 patients with advanced EGFR-mutated NSCLC who received EGFR-TKI monotherapy at Hiroshima University Hospital between November 2009 and August 2023. Pre-treatment serum levels of total VEGF-A (tVEGF-A), VEGF

resultsThe ORR was 78.1%, and the median PFS and OS were 7.5 and 31.8 months, respectively. Serum VEGF

conclusionHigher levels of serum VEGF

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsVascular Endothelial Growth Factor AAdultAgedAged, 80 and overBiomarkers, TumorErbB ReceptorsFemaleHumansMaleMiddle AgedMutationPrognosisProtein IsoformsBiomarkers, TumorEGFR protein, humanErbB ReceptorsProtein IsoformsProtein Kinase InhibitorsVascular Endothelial Growth Factor AVEGFA protein, humanBiomarkerEpidermal growth factor receptorNon-small cell lung cancerTyrosine kinase inhibitorVascular endothelial growth factor-AVEGF121

Identifiers

PMID42262689
PMCPMC13401580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.